... PRINCETON N.J. June 3 /- Medarex Inc.(N...About Medarex ...Medarex is a biopharmaceutical company focused on the discoverydevel...Medarex(R) the Medarex logo and UltiMAb(R) are registered trademarks...

PRINCETON, N.J., June 3 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that it is scheduled to present at the 29th
Annual Goldman Sachs Healthcare Conference at 1:25 p.m. Eastern Time on
Tuesday, June 10, 2008. The event will be webcast live and will be
available in the Investor Relations section of the Medarex website at
http://www.medarex.com. An archived edition of the presentation will be available
following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 40 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase 3 clinical trials or the subject of regulatory
applications for marketing authorization. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its Web site at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.

(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...

(Date:12/7/2016)... ... December 07, 2016 , ... A new study published in ... previously treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute ... of blood sampling may improve the value of a blood-based test.” The study ...

(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...

(Date:12/6/2016)... Dec. 6, 2016 Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...